Asymchem Laboratories Tian Jin Co Ltd - Asset Resilience Ratio
Asymchem Laboratories Tian Jin Co Ltd (002821) has an Asset Resilience Ratio of 5.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Asymchem Laboratories Tian Jin Co Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Asymchem Laboratories Tian Jin Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Asymchem Laboratories Tian Jin Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Asymchem Laboratories Tian Jin Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.05 Billion | 5.07% |
| Total Liquid Assets | CN¥1.05 Billion | 5.07% |
Asset Resilience Insights
- Limited Liquidity: Asymchem Laboratories Tian Jin Co Ltd maintains only 5.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Asymchem Laboratories Tian Jin Co Ltd Industry Peers by Asset Resilience Ratio
Compare Asymchem Laboratories Tian Jin Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Asymchem Laboratories Tian Jin Co Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Asymchem Laboratories Tian Jin Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.51% | CN¥1.12 Billion ≈ $163.39 Million |
CN¥20.28 Billion ≈ $2.97 Billion |
-2.48pp |
| 2024-12-31 | 7.98% | CN¥1.54 Billion ≈ $225.32 Million |
CN¥19.29 Billion ≈ $2.82 Billion |
-1.66pp |
| 2023-12-31 | 9.64% | CN¥1.91 Billion ≈ $278.88 Million |
CN¥19.77 Billion ≈ $2.89 Billion |
-2.15pp |
| 2022-12-31 | 11.79% | CN¥2.15 Billion ≈ $314.77 Million |
CN¥18.24 Billion ≈ $2.67 Billion |
+9.15pp |
| 2021-12-31 | 2.65% | CN¥401.20 Million ≈ $58.71 Million |
CN¥15.16 Billion ≈ $2.22 Billion |
+2.42pp |
| 2018-12-31 | 0.22% | CN¥7.11 Million ≈ $1.04 Million |
CN¥3.19 Billion ≈ $466.12 Million |
-2.06pp |
| 2015-12-31 | 2.28% | CN¥29.01 Million ≈ $4.25 Million |
CN¥1.27 Billion ≈ $186.06 Million |
+2.27pp |
| 2014-12-31 | 0.01% | CN¥88.56K ≈ $12.96K |
CN¥1.06 Billion ≈ $154.84 Million |
-0.05pp |
| 2013-12-31 | 0.06% | CN¥502.60K ≈ $73.55K |
CN¥913.19 Million ≈ $133.63 Million |
-- |
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more